Venlafaxine 93413-69-5
Venlafaxine (Effexor, Efexor) is an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI). It has a similar chemical structure to the opioid derivative tramadol, and has the tertiary amine functional group necessary for µ-opioid receptor recognition (cf. lefetamine), though it is unknown whether it has an opioid agonist effect. It is surprisingly effective in treating depression in heroin and other opioid addicts compared to all other conventional antidepressants. First introduced by Wyeth in 1993, now marketed by Pfizer, it is licensed for the treatment of major depressive disorder (MDD), as a treatment for generalized anxiety disorder, and comorbid indications in certain anxiety disorders with depression. In 2007, venlafaxine was the sixth most commonly prescribed antidepressant on the U. S. retail market, with 17. 2 million prescriptions. In children and adolescents, venlafaxine (like other antidepressants) has a potential to increase suicidal thoughts, attempts and events of self-harm.
Indications
Approved
Venlafaxine is used primarily for the treatment of major depression in adults. Judged by the same criteria, venlafaxine was similar in efficacy to the atypical antidepressant bupropion (Wellbutrin); however, the remission rate was significantly lower for venlafaxine. In a double-blind study, patients who did not respond to an SSRI were switched to venlafaxine or citalopram. Similar improvement was observed in both groups.
Off-label/investigational uses{{anchor
Off-label / investigational uses
| Systematic (IUPAC) name: | (RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol |
|---|---|
| Venlafaxine CAS number: | 93413-69-5 |
| ATC code: | N06AX16 |
| PubChem: | 5656 |
| DrugBank: | APRD00125 |
| Formula: | C17 H27 N1 O2 |
| Molecular mass: | 277.402 g/mol |
| Venlafaxine Assay/Purity: | Typically NLT 98% |
